35 related articles for article (PubMed ID: 10357404)
1. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Falk S; Anthoney A; Eatock M; Van Cutsem E; Chick J; Glen H; Valle JW; Drolet DW; Albert D; Ferry D; Ajani J
Br J Cancer; 2006 Aug; 95(4):450-6. PubMed ID: 16880795
[TBL] [Abstract][Full Text] [Related]
2. Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study.
Liu P; McMenamin ÚC; Spence AD; Johnston BT; Coleman HG; Cardwell CR
BMC Cancer; 2019 Oct; 19(1):1017. PubMed ID: 31664951
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer.
Wang FY; Huang XM; Cao YQ; Cao J; Ni J; Li K; Lu M; Huang XE
J Gastrointest Cancer; 2024 Apr; ():. PubMed ID: 38668776
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
Chen XZ; Jiang K; Hu JK; Zhang B; Gou HF; Yang K; Chen ZX; Chen JP
World J Gastroenterol; 2008 May; 14(17):2715-22. PubMed ID: 18461656
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.
Kobayashi M; Oba K; Sakamoto J; Kondo K; Nagata N; Okabayashi T; Namikawa T; Hanazaki K
Gastric Cancer; 2007; 10(1):52-7. PubMed ID: 17334719
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.
Kobayashi M; Sakamoto J; Namikawa T; Okamoto K; Okabayashi T; Ichikawa K; Araki K
World J Gastroenterol; 2006 Mar; 12(9):1412-5. PubMed ID: 16552811
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity.
Bar-Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
Med Oncol; 2003; 20(3):291-4. PubMed ID: 14514979
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Ajani JA; Fairweather J; Pisters PW; Charnsangavej C
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):19-21. PubMed ID: 11200143
[TBL] [Abstract][Full Text] [Related]
10. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
Lokich JJ; Sonneborn H; Anderson NR; Bern MM; Coco FV; Dow E; Oliynyk P
Cancer; 1999 Jun; 85(11):2347-51. PubMed ID: 10357404
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.
Sharma A; Raina V; Lokeshwar N; Deo SV; Shukla NK; Mohanti BK
Indian J Cancer; 2006; 43(1):16-9. PubMed ID: 16763357
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
13. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with upper gastrointestinal carcinomas.
Ajani JA
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
